Navigation Links
Columbia study shows widely used artery clearing device does not help patients during heart attack

Interventional cardiologists from Columbia University Medical Center have shown that a commonly used procedure to remove fatty debris from blocked arteries during a heart attack does not improve patient outcomes.

The procedure, called distal microcirculatory protection, is commonly and successfully used during angioplasty in vein grafts and stenting in carotid arteries. The study, published in the March 2 issue of the Journal of the American Medical Association, found that the devices were successful in removing debris from the arteries in angioplasties during heart attacks, but it showed that there was no benefit to the patient.

"It's not entirely clear why the devices failed to improve patient outcomes, but it's possible that so much damage happens during a heart attack that distal protection is simply too little, too late," said Gregg W. Stone, M.D., director of research and education for the Center for Interventional Vascular Therapy at Columbia University Medical Center and New York-Presbyterian Hospital, and vice chairman of the Cardiovascular Research Foundation.

The study, which was conducted in 38 institutions in seven countries, examined 501 patients who were having heart attacks, half of whom received distal protection.

During angioplasty procedures, fatty deposits in the arteries can be dislodged and clog arteries further downstream. Distal protection devices use a specialized guidewire and catheter to collect and remove this debris.

The study evaluated the efficacy of distal protection devices using several measures, including evaluating patient ST segments ?a portion of the EKG that can indicate heart damage when it is elevated. The study showed that the percentage of patients who had normalization of the ST segment were the same, whether or not distal protection devices were used.

Within six months of the heart attack, patients had a comparable frequency of major adverse cardiac events regardless of wheth er or not they received the treatment.

The study also measured the size of the heart attacks by measuring the uptake of a tracer in the heart, and found that there was no difference for patients who received distal protection.

According to Dr. Stone, not using distal protection devices will reduce the cost of angioplasties during heart attacks, and could avoid potential complications caused by the devices.


'"/>

Source:Columbia University Medical Center


Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. Columbia scientists develop cancer terminator viruses
3. Contaminants linked to sturgeon decline in Columbia river
4. Columbia University licenses next-generation DNA sequencing technology
5. New bird discovered on unexplored Columbian mountain
6. Columbia scientists determine 3-dimensional structure of cells fuel gauge
7. Bioartificial kidney under study at MCG
8. W.M. Keck Foundation funds study of friendly microbes
9. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
10. Genome-wide mouse study yields link to human leukemia
11. Clam embryo study shows pollutant mixture adversely affects nerve cell development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The ... Identification Systems) ... Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is part of ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... , ... December 01, 2016 , ... ... long-term client Nanowear on their recent FDA Class II 510(k) clearance for their ... significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. ...
(Date:12/2/2016)... a world leader in rapid infectious disease tests, introduced the Company,s newest product, the ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , , bioLytical was invited by the ... INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
(Date:11/30/2016)... Biotest Pharmaceuticals Corporation (BPC), a leading manufacturer ... addition of its newest plasma collection center located at ... The 15,200 square foot state-of-the-art facility officially opened its ... the total number of BPC,s plasma collection centers to ... Chief Executive Officer said "We are pleased to become ...
(Date:11/30/2016)... November 2016   Merck , ein ... Unterzeichnung einer Reihe von Vereinbarungen mit Evotec ... AG Screeningleistungen für Mercks Palette genetischer Reagenzien ... auf diese Bibliotheken in Kombination mit Evotecs ... Weg zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
Breaking Biology Technology: